ANI Pharmaceuticals | ANIP - Cost Of Sales


ANI Pharmaceuticals reported $114.5M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
Assertio Holdings USD 8.89M 2.29M Jun/2024
Aurora Cannabis CAD 88.61M 30.53M Dec/2025
Canopy Growth CAD 53.08M 8.3M Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Heron Therapeutics USD 11.12M 795K Dec/2025
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novartis USD 3.54B 7M Dec/2025
Omeros USD 33.16M 18.52M Jun/2024
Perrigo USD 643.7M 103.7M Mar/2026
Sun Pharmaceuticals INR 36.77B 348M Dec/2025
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026